Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
A video roundup of the week’s top industry news stories.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
Contract Pharma Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
If you’ve got the money, I’ve got the time
May 30, 2012
By: Gil Roth
President, Pharma & Biopharma Outsourcing Association
At INTERPHEX in early May, outsourcing guru Jim Miller of PharmSource gave a presentation on new bio/pharma business models, and mentioned that tax breaks in different countries constitute a challenge for CMOs. If a country creates a big tax advantage for a large pharma, the large pharma may find it more beneficial to build a new facility or upgrade an existing one and insource more of its work. A number of CMOs I met with during INTERPHEX wanted to talk to me about that point, to the exclusion of the rest of the presentation. Like most Americans, I do my fair share of complaining about taxes, but I get the feeling that Jim struck a nerve with that topic. Of course, taxes are a pretty sensitive matter. We all feel that we pay too much, someone else should be paying more, and the money doesn’t get spent wisely. Still, we make our way and render unto Caesar, paying out numbers unreflected in this year’s Salary Survey. Few of us are in any position to do anything about it, at least not like Eduardo Saverin did. The news recently broke that Mr. Saverin, co-founder of Facebook, has renounced his U.S. citizenship to become a . . . Singaporean? The move was made last September, but its announcement coincided with Facebook’s IPO. The argument is that Mr. Saverin chose to reside in Singapore in order to avoid capital gains taxes in the years ahead, since his shares in Facebook are valued between $2 or $4 billion. Singapore has a top income tax of 20%, no capital gains tax, and no estate tax, for Mr. Saverin’s heirs. Mr. Saverin was pilloried in the press by people who would likely have done the same thing if they were in his shoes, and the nudnik senior senator from New York, Charles Schumer, has proposed a law to heavily penalize people who try to make such a move. It was a grandstanding gesture by a senator renowned for grandstanding, so it likely won’t be enacted into law. Still, Mr. Saverin may not be able to set foot in the U.S. again, since immigration law bars re-entry by people who renounced citizenship for tax purposes. The same week that Mr. Saverin’s (alleged) tax-dodge went public, my wife and I went to see Willie Nelson in concert. It was a fantastic experience; at 79, Mr. Nelson’s a living legend and I was amazed to see him perform for nearly 90 minutes without a break. He managed to evoke some beautiful sound from “Trigger,” a guitar that’s slightly older than I am, hitting his peak with a long, gorgeous, South-western solo leading into I Never Cared For You. On the drive home, we discussed why a man five years older than my dad is still out playing shows. We both recalled that he had some tax problems in the past, so my wife looked up his tax history online. As it turns out, the IRS came after him for an astounding $32 million in unpaid taxes back in the early ’90s, one of the largest penalties ever levied at a private individual.* That got negotiated down, and Mr. Nelson eventually won an undisclosed settlement from his accounting firm, which allegedly advised him to invest his money in some dodgy tax shelters, but he still went through the ignominy of having his assets stripped and auctioned before he was able to pay off his debt and start over. Which may help explain why he’s on the road again. I hope when I’m his age I’ll be even a quarter as good at whatever the heck I do as he is at playing the guitar. But I’m also hoping I won’t have to be. *Big pharma, needless to say, has Mr. Nelson beat when it comes to huge tax penalties. Gil Roth Editor • [email protected] / twitter.com/contractpharma
Enter the destination URL
Or link to existing content
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !